Elevated Dihydrotestosterone is Associated with Testosterone Induced Erythrocytosis

Area of Science:

• Endocrinology
• Hematology

Background:

• Erythrocytosis is a common adverse effect of testosterone therapy.
• The precise mechanisms driving testosterone-mediated erythropoiesis are not fully understood.

Purpose of the Study:

• To investigate risk factors associated with erythrocytosis in men undergoing testosterone therapy.
• To explore the relationship between testosterone formulations, 5α-reductase inhibitor use, and hematocrit changes.

Main Methods:

• Retrospective review of 179 hypogonadal men on testosterone therapy.
• Analysis of demographic data, testosterone formulation, treatment duration, and 5α-reductase inhibitor use.
• Measurement of serum hormone levels (dihydrotestosterone, testosterone, FSH, LH) and hematocrit, with correlation analysis.

Main Results:

• 20.1% of patients developed erythrocytosis (hematocrit ≥50%) at a median of 7 months.
• Injectable testosterone use was associated with greater hematocrit changes compared to other formulations.
• Higher post-treatment dihydrotestosterone levels correlated with increased hematocrit, while 5α-reductase inhibitor use was associated with lower hematocrit changes.

Conclusions:

• Dihydrotestosterone may play a role in testosterone therapy-induced erythrocytosis.
• Monitoring dihydrotestosterone levels during testosterone therapy is recommended.
• 5α-reductase inhibitors may offer a therapeutic option for managing erythrocytosis in these patients.